CLINICAL_TRIALS
trial_result
· 2008-02-21
Clinical Trial Update: Luteal Phase Administration of Paroxetine for the Treatment of PMDD [Phase 3]
Summary
A Phase 3 clinical trial evaluated luteal-phase paroxetine for treating Premenstrual Dysphoric Disorder; the study status is completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Hamilton Health Sciences Corporation | Conditions: Premenstrual Dysphoric Disorder | Phase 3 | Status: COMPLETED